-0.16%
7.78%
7.43%
18.23%
23.30%
57.40%
82.59%
AI Spotlight on SYK
Company Description
Stryker Corporation operates as a medical technology company.The company operates through two segments, MedSurg and Neurotechnology, and Orthopaedics and Spine.The Orthopaedics and Spine segment provides implants for use in hip and knee joint replacements, and trauma and extremities surgeries.
This segment also offers spinal implant products comprising cervical, thoracolumbar, and interbody systems that are used in spinal injury, deformity, and degenerative therapies.The MedSurg and Neurotechnology segment offers surgical equipment and surgical navigation systems, endoscopic and communications systems, patient handling, emergency medical equipment and intensive care disposable products, reprocessed and remanufactured medical devices, and other medical device products that are used in various medical specialties.This segment also provides neurotechnology products, which include products used for minimally invasive endovascular techniques; products for brain and open skull based surgical procedures; orthobiologic and biosurgery products, such as synthetic bone grafts and vertebral augmentation products; minimally invasive products for the treatment of acute ischemic and hemorrhagic stroke; and craniomaxillofacial implant products, including cranial, maxillofacial, and chest wall devices, as well as dural substitutes and sealants.
The company sells its products to doctors, hospitals, and other healthcare facilities through company-owned subsidiaries and branches, as well as third-party dealers and distributors in approximately 75 countries.Stryker Corporation was founded in 1941 and is headquartered in Kalamazoo, Michigan.
Market Data
| Last Price | 390.43 |
| Change Percentage | -0.16% |
| Open | 394.15 |
| Previous Close | 391.07 |
| Market Cap ( Millions) | 148838 |
| Volume | 1681734 |
| Year High | 406.19 |
| Year Low | 314.93 |
| M A 50 | 377.99 |
| M A 200 | 353.91 |
Financial Ratios
| FCF Yield | 2.15% |
| Dividend Yield | 0.83% |
| ROE | 11.73% |
| Debt / Equity | 28.36% |
| Net Debt / EBIDTA | 190.75% |
| Price To Book | 3.46 |
| Price Earnings Ratio | 49.74 |
| Price To FCF | 46.44 |
| Price To sales | 6.59 |
| EV / EBITDA | 35.17 |
News
- Jan -30 - Will Cheaper AI Models Like DeepSeek Become a Boon? 3 Stocks to Watch
- Jan -29 - Stryker's Strategic Moves Impress Analysts, Spine Implant Sale and NARI Deal Set to Drive Future Growth
- Jan -29 - Stryker Stock Falls on Deal to Sell Its U.S. Spinal Implants Business
- Jan -29 - SYK Stock Down Despite Q4 Earnings Beat and Spine Biz Divestment Plans
- Jan -29 - Stryker Corporation (SYK) Q4 2024 Earnings Conference Call Transcript
- Jan -29 - Stryker (SYK) Q4 Earnings: Taking a Look at Key Metrics Versus Estimates
- Jan -28 - Stryker (SYK) Q4 Earnings and Revenues Surpass Estimates
- Jan -28 - Stryker forecasts 2025 profit above estimates on robust demand for surgical devices
- Jan -28 - Overlooked Stock: SYK
- Jan -28 - Stryker announces definitive agreement for the sale of its U.S. spinal implants business and plans to sell related international business
- Jan -28 - Stryker announces the retirement of Glenn S. Boehnlein and the promotion of Preston Wells to Vice President, Chief Financial Officer
- Jan -28 - Stryker reports 2024 operating results and 2025 outlook
- Jan -27 - Strong Segmental Performance to Drive Stryker's Q4 Earnings?
- Jan -27 - Stryker: A Cool Name For An Awesome Company, But Is It A Buy Ahead Of Earnings?
- Jan -24 - PAHC vs. SYK: Which Stock Should Value Investors Buy Now?
- Jan -23 - Stryker (SYK) Q4 Earnings on the Horizon: Analysts' Insights on Key Performance Measures
- Jan -17 - Stryker commences tender offer for all outstanding shares of common stock of Inari Medical, Inc.
- Jan -08 - PAHC or SYK: Which Is the Better Value Stock Right Now?
- Jan -07 - INARI MEDICAL INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Inari Medical, Inc. - NARI
- Jan -07 - Stryker Stock Falls Despite the Agreement to Acquire Inari Medical
Business Breakdown
Expected Mid-Term Growth
Segment n°1 -> MedSurg and Neurotechnology
Expected Growth : 6.5 %
What the company do ?
MedSurg and Neurotechnology from Stryker Corporation refers to medical and surgical products, including neurotechnology solutions for neurosurgical and orthopedic procedures.
Why we expect these perspectives ?
Stryker's MedSurg and Neurotechnology segments' 6.5% growth is driven by increasing demand for minimally invasive surgical instruments, robotic-assisted surgery, and neurovascular products. Expanding hospital and outpatient surgery center markets, an aging population, and innovative product launches also contribute to growth.
Segment n°2 -> Orthopaedics and Spine
Expected Growth : 7.5 %
What the company do ?
Orthopaedics and Spine from Stryker Corporation provides innovative implants, instruments, and technologies for joint reconstruction, trauma, and spine procedures, enhancing patient care and outcomes.
Why we expect these perspectives ?
Stryker's Orthopaedics and Spine segment growth is driven by increasing demand for joint replacement and spine surgeries, fueled by an aging population and rising prevalence of osteoarthritis. Additionally, advancements in robotic-assisted surgery and minimally invasive procedures are driving adoption of Stryker's innovative products, such as Mako robotic-arm assisted surgery.
Stryker Corporation Products
| Product Range | What is it ? |
|---|---|
| Orthopaedic Implants | Stryker's Orthopaedic Implants segment offers a range of products, including hip, knee, and trauma implants, as well as bone cement and accessories. |
| MedSurg Equipment | Stryker's MedSurg Equipment segment provides a variety of medical devices, including hospital beds, stretchers, and surgical navigation systems. |
| Neurotechnology and Spine | Stryker's Neurotechnology and Spine segment offers products for neurosurgery, orthobiologics, and spinal implant systems. |
| Instruments | Stryker's Instruments segment provides a range of surgical instruments, including electrosurgical, endoscopic, and orthopaedic instruments. |
Stryker Corporation's Porter Forces
Threat Of Substitutes
Stryker Corporation operates in the medical technology industry, where substitutes are limited. However, the company faces competition from alternative medical procedures and treatments, which could potentially substitute its products.
Bargaining Power Of Customers
Stryker Corporation sells its products to hospitals, clinics, and other healthcare providers, which have limited bargaining power due to the specialized nature of the company's products.
Bargaining Power Of Suppliers
Stryker Corporation relies on a diverse range of suppliers for raw materials, components, and services. While some suppliers may have bargaining power, the company's diversified supply chain mitigates this risk.
Threat Of New Entrants
The medical technology industry has high barriers to entry, including significant research and development costs, regulatory hurdles, and the need for specialized expertise. This limits the threat of new entrants.
Intensity Of Rivalry
The medical technology industry is highly competitive, with several established players competing for market share. Stryker Corporation faces intense rivalry from companies such as Johnson & Johnson, Medtronic, and Zimmer Biomet.
Capital Structure
| Value | |
|---|---|
| Debt Weight | 41.14% |
| Debt Cost | 3.95% |
| Equity Weight | 58.86% |
| Equity Cost | 8.51% |
| WACC | 6.63% |
| Leverage | 69.89% |
Stryker Corporation : Quality Control
Stryker Corporation passed 5 out of 9 key points:
Historical Valuation
Price/Earnings Ratio
Margin Valuation
Peers Valuation
Competitors
| Company | Rational |
|---|---|
| REGN | Regeneron Pharmaceuticals, Inc. discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular … |
| BSX | Boston Scientific Corporation develops, manufactures, and markets medical devices for use in various interventional medical specialties worldwide. It operates through three segments: MedSurg, Rhythm and Neuro, and Cardiovascular. The company … |
| DXCM | DexCom, Inc., a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems in the United States and internationally. The company provides its systems … |
| ABT | Abbott Laboratories, together with its subsidiaries, discovers, develops, manufactures, and sells health care products worldwide. It operates in four segments: Established Pharmaceutical Products, Diagnostic Products, Nutritional Products, and Medical Devices. … |
| JNJ | Johnson & Johnson, together with its subsidiaries, researches and develops, manufactures, and sells various products in the healthcare field worldwide. The company's Consumer Health segment offers baby care products under … |
Peers Metrics
DCF BETA
Expected Cash-Flows
Scoring Insights
Peers Group Analysis
🥇
J&J
A-Score
1-Year Total Return ->
🥈
Abbott
A-Score
1-Year Total Return ->
🥉
Stryker
A-Score
1-Year Total Return ->
4
Boston Scientific
A-Score
1-Year Total Return ->
5
Regeneron Pharmaceuticals
A-Score
1-Year Total Return ->
6
